Buchumschlag

International Myeloma Society/International Myeloma working group consensus recommendations on the definition of high-risk multiple myeloma

Despite significant improvements in survival of patients with multiple myeloma (MM), outcomes remain heterogeneous, and a significant proportion of patients experience suboptimal outcomes. Importantly, traditional prognostic factors based on data from patients treated with older therapies no longer...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: Avet-Loiseau, Hervé (VerfasserIn) , Davies, Faith E. (VerfasserIn) , Samur, Mehmet K. (VerfasserIn) , Corre, Jill (VerfasserIn) , D'Agostino, Mattia (VerfasserIn) , Kaiser, Martin F. (VerfasserIn) , Raab, Marc-Steffen (VerfasserIn) , Weinhold, Niels (VerfasserIn) , Gutierrez, Norma C. (VerfasserIn) , Paiva, Bruno (VerfasserIn) , Neri, Paola (VerfasserIn) , Weisel, Katja (VerfasserIn) , Maura, Francesco (VerfasserIn) , Walker, Brian A. (VerfasserIn) , Bustoros, Mark (VerfasserIn) , Stewart, A. Keith (VerfasserIn) , Usmani, Saad Z. (VerfasserIn) , Hillengass, Jens (VerfasserIn) , Chng, Wee Joo (VerfasserIn) , Keats, Jonathan J. (VerfasserIn) , Martinez-Lopez, Joaquin (VerfasserIn) , Sperling, Adam S. (VerfasserIn) , Touzeau, Cyrille (VerfasserIn) , Zhan, Fenghuang (VerfasserIn) , Raje, Noopur S. (VerfasserIn) , Cavo, Michele (VerfasserIn) , Bolli, Niccolò (VerfasserIn) , Ghobrial, Irene M. (VerfasserIn) , Dhodapkar, Madhav V. (VerfasserIn) , Jagannath, Sundar (VerfasserIn) , Spencer, Andrew (VerfasserIn) , Parekh, Samir (VerfasserIn) , Bahlis, Nizar J. (VerfasserIn) , Lonial, Sagar (VerfasserIn) , Sonneveld, Pieter (VerfasserIn) , Bergsagel, Leif (VerfasserIn) , Orlowski, Robert Z. (VerfasserIn) , Morgan, Gareth (VerfasserIn) , Mateos, María Victoria (VerfasserIn) , Rajkumar, S. Vincent (VerfasserIn) , Miguel, Jesus F. San (VerfasserIn) , Anderson, Kenneth C. (VerfasserIn) , Moreau, Philippe (VerfasserIn) , Kumar, Shaji (VerfasserIn) , Prósper, Felipe (VerfasserIn) , Munshi, Nikhil C. (VerfasserIn)
Dokumenttyp: Article (Journal)
Sprache:Englisch
Veröffentlicht: August 2025
In: Journal of clinical oncology
Year: 2025, Jahrgang: 43, Heft: 24, Pages: 2739-2751
ISSN:1527-7755
DOI:10.1200/JCO-24-01893
Online-Zugang:Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1200/JCO-24-01893
Verlag, lizenzpflichtig, Volltext: https://ascopubs.org/doi/10.1200/JCO-24-01893
Volltext
Verfasserangaben:Hervé Avet-Loiseau, MD, PhD, Faith E. Davies, MD, Mehmet K. Samur, PhD, Jill Corre, PharmD, PhD, Mattia D’Agostino, MD, Martin F. Kaiser, MD, Marc S. Raab, MD, Niels Weinhold, PhD, Norma C. Gutierrez, MD, PhD, Bruno Paiva, PhD, Paola Neri, MD, Katja Weisel, MD, Francesco Maura, MD, Brian A. Walker, PhD, Mark Bustoros, MD, A. Keith Stewart, MB, CHB, Saad Z. Usmani, MD, Jens Hillengass, MD, PhD, Wee Joo Chng, MD19, Jonathan J. Keats, PhD, Joaquin Martinez-Lopez, MD, Adam S. Sperling, MD, PhD, Cyrille Touzeau, MD, Fenghuang Zhan, PhD, Noopur S. Raje, MD, Michele Cavo, MD, Niccolò Bolli, MD, PhD, Irene M. Ghobrial, MD, Madhav V. Dhodapkar, MD, Sundar Jagannath, MD, Andrew Spencer, MD, Samir Parekh, MD, Nizar J. Bahlis, MD, Sagar Lonial, MD, Pieter Sonneveld, MD, PhD, Leif Bergsagel, MD, Robert Z. Orlowski, MD, PhD, Gareth Morgan, MD, María Victoria Mateos, MD, S. Vincent Rajkumar, MD, Jesus F. San Miguel, MD, Kenneth C. Anderson, MD, Philippe Moreau, MD, Shaji Kumar, MD, Felipe Prósper, MD, and Nikhil C. Munshi, MD
Beschreibung
Zusammenfassung:Despite significant improvements in survival of patients with multiple myeloma (MM), outcomes remain heterogeneous, and a significant proportion of patients experience suboptimal outcomes. Importantly, traditional prognostic factors based on data from patients treated with older therapies no longer capture prognosis accurately in the contemporary era of novel triplet or quadruplet therapies. Therefore, risk stratification requires refinement in the context of available and investigational treatment options in routine practice and clinical trials, respectively. The current identification of high-risk MM (HRMM) in routine practice is based on the Revised International Staging System, which stratifies patients using a combination of widely available serum biomarkers and chromosomal abnormalities assessed via fluorescence in situ hybridization. In recent years, a substantial body of evidence concerning additional clinical, biological, and molecular/genomic prognostic factors has accumulated, along with new MM risk stratification tools and consensus reports. The International Myeloma Society, along with the International Myeloma Working Group, convened an Expert Panel with the primary aim of revisiting the definition of HRMM and formulating a practical and data-driven consensus definition, based on new evidence from molecular/genomic assays, updated clinical data, and contemporary risk stratification concepts. The Panel proposes the following Consensus Genomic Staging (CGS) of HRMM which relies upon the presence of at least one of these abnormalities: (1) del(17p), with a cutoff of >20%clonal fraction, and/or TP53mutation; (2) an IgH translocation including t(4;14), t(14;16), or t(14;20) along with 1q1 and/or del(1p32); (3) monoallelic del(1p32) along with 1q1 or biallelic del(1p32); or (4) b2 microglobulin ≥5.5 mg/L with normal creatinine (<1.2 mg/dL).
Beschreibung:Veröffentlicht: 09. Juni 2025
Gesehen am 22.01.2026
Beschreibung:Online Resource
ISSN:1527-7755
DOI:10.1200/JCO-24-01893

Ähnliche Einträge